646 related articles for article (PubMed ID: 36529238)
1. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
Wang Z; Wang Y; Gao P; Ding J
Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
[TBL] [Abstract][Full Text] [Related]
2. The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma.
Kou L; Xie X; Chen X; Li B; Li J; Li Y
Cancer Immunol Immunother; 2023 Dec; 72(12):3953-3969. PubMed ID: 37917364
[TBL] [Abstract][Full Text] [Related]
3. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
Chami P; Diab Y; Khalil DN; Azhari H; Jarnagin WR; Abou-Alfa GK; Harding JJ; Hajj J; Ma J; El Homsi M; Reyngold M; Crane C; Hajj C
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069095
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
Harkus U; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
Semin Cancer Biol; 2022 Nov; 86(Pt 3):799-815. PubMed ID: 35065242
[TBL] [Abstract][Full Text] [Related]
5. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.
Akbulut Z; Aru B; Aydın F; Yanıkkaya Demirel G
Front Immunol; 2024; 15():1379622. PubMed ID: 38638433
[TBL] [Abstract][Full Text] [Related]
7. Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma.
Yan ZJ; Yu CT; Chen L; Wang HY
Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36882021
[TBL] [Abstract][Full Text] [Related]
8. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
9. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
[TBL] [Abstract][Full Text] [Related]
10. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
Front Immunol; 2021; 12():676922. PubMed ID: 34335575
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
12. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
Liu L; Qin S; Zhang Y
Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
[TBL] [Abstract][Full Text] [Related]
13. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Oura K; Morishita A; Tani J; Masaki T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
[TBL] [Abstract][Full Text] [Related]
14. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
15. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
[TBL] [Abstract][Full Text] [Related]
16. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
Carloni R; Rizzo A; Ricci AD; Frega G; Federico AD; Palloni A; Marco MD; Gadaleta-Caldarola G; Brandi G
Future Oncol; 2022 Mar; 18(8):1023-1034. PubMed ID: 35109664
[TBL] [Abstract][Full Text] [Related]
17. Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma.
Sharma R; Motedayen Aval L
Front Immunol; 2021; 12():652007. PubMed ID: 33790915
[TBL] [Abstract][Full Text] [Related]
18. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies.
Atkins MB; Ascierto PA; Feltquate D; Gulley JL; Johnson DB; Khushalani NI; Sosman J; Yap TA; Kluger H; Sullivan RJ; Tawbi H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918225
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.
Tao S; Liang S; Zeng T; Yin D
Front Immunol; 2022; 13():1043667. PubMed ID: 36685594
[TBL] [Abstract][Full Text] [Related]
20. Advances in Immunotherapy for Hepatocellular Carcinoma (HCC).
Bicer F; Kure C; Ozluk AA; El-Rayes BF; Akce M
Curr Oncol; 2023 Nov; 30(11):9789-9812. PubMed ID: 37999131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
